135 related articles for article (PubMed ID: 340032)
1. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
[TBL] [Abstract][Full Text] [Related]
3. Piperazinedione in patients with advanced malignant melanoma: a Southwest Oncology Group study.
Al-Sarraf M; Thigpen T; Groppe CW; Haut A; Padilla F
Cancer Treat Rep; 1978 Jul; 62(7):1101-3. PubMed ID: 356973
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of amsacrine (m-AMSA) in advanced lymphomas: a Southwest Oncology Group study.
Weick JK; Jones SE; Ryan DH
Cancer Treat Rep; 1983 May; 67(5):489-92. PubMed ID: 6687839
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study.
Rossof AH; Coltman CA; Jones SE; Talley RW
Cancer Treat Rep; 1979; 63(9-10):1605-8. PubMed ID: 498159
[TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation of piperazinedione in patients with advanced cancer.
Currie V; Woodcock T; Tan C; Krakoff I; Young C
Cancer Treat Rep; 1979 Jan; 63(1):73-6. PubMed ID: 369694
[TBL] [Abstract][Full Text] [Related]
7. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
Alberts DS; Balcerzak SP; Bonnet JD; Stephens RL
Cancer Treat Rep; 1985 Nov; 69(11):1321-3. PubMed ID: 4092195
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of pyrazofurin, alone and in combination with trifluorothymidine, in non-Hodgkin's lymphoma.
Warrell RP; Currie V; Kempin S; Young C
Cancer Treat Rep; 1979 Aug; 63(8):1423-5. PubMed ID: 113097
[TBL] [Abstract][Full Text] [Related]
10. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
11. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
12. DTIC (NSC-45388) studies in the southwest oncology group.
Costanzi JJ
Cancer Treat Rep; 1976 Feb; 60(2):189-92. PubMed ID: 769972
[TBL] [Abstract][Full Text] [Related]
13. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
14. [Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].
Masaoka T; Ogawa M; Inoue K; Sanpi K; Kuraishi Y; Toki H; Tamura K; Takagi T; Shibata A; Hirano M; Ezaki K; Shirakawa S; Matsuda T; Kimura I
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1857-65. PubMed ID: 11729478
[TBL] [Abstract][Full Text] [Related]
15. Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas.
O'Connell MJ; Begg CB; Silverstein MN; Glick JH; Oken MM
Cancer Treat Rep; 1980; 64(12):1355-8. PubMed ID: 7008938
[TBL] [Abstract][Full Text] [Related]
16. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
[TBL] [Abstract][Full Text] [Related]
17. [Early phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
Tominaga N; Teshima H; Hiraoka A; Masaoka T; Ariyoshi Y; Suzuki H; Kimura I; Ohnoshi T; Hayashi K; Arima T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2441-6. PubMed ID: 1952963
[TBL] [Abstract][Full Text] [Related]
18. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of piperazinedione in metastatic breast carcinoma.
Palmer RL; Samal BA; Vaughn CB; Tranum BL
Cancer Treat Rep; 1977 Dec; 61(9):1711-2. PubMed ID: 340035
[No Abstract] [Full Text] [Related]
20. Phase II trial of piperazinedione in malignant melanoma: a report by the Southeastern Cancer Study Group.
Presant CA; Bartolucci AA; Ungaro P; Oldham R
Cancer Treat Rep; 1979 Aug; 63(8):1367-9. PubMed ID: 476710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
